Identification of key genes involved in papillary thyroid cancer by bioinformatics tools

Main Article Content

Lutfiye Kadioglu Dalkilic
Semih Dalkilic


Papillary thyroid cancer, gene expression, bioinformatics


Study Objectives: Thyroid cancer is the sixth most common type of cancer among women worldwide, with an increasing incidence. It is the most common endocrine cancer and it is seen in 1.7% of all cancers. We aimed to detect genes whose expression level varies in this pathology by using gene expression data obtained from papillary thyroid cancer tissue. Methods: Microarray data selected for bioinformatic analysis is Gene Expression data stored with GSE35570 code in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database. Thyroid cancer and healthy control groups were compared, then variance filtering was applied and as a result, gene lists with different expression levels were obtained between the compared groups. Totally, 1209 genes were differentially expressed between these two groups. Results: We have determined that SFTPB, HMGA2, ARHGAP36, SYTL5, LRRK2, PRR15, DPP4, TENM1, SCEL genes were upregulated in papillary thyroid cancer group and CCL21, COL9A3, FBLN1, LRP1B, PROM1, NEB, CDH16, TFCP2L1 genes were downregulated. Conclusion: We have concluded that these identified genes can be used as candidate biomarker genes for diagnosis of papillary thyroid cancer.


Download data is not yet available.
Abstract 21 | PDF Downloads 8


1. Lodewijk L, Prins AM, Kist JW, Valk GD, Kranenburg O, Rinkes IH, et al. The value of miRNA in diagnosing thyroid cancer: a systematic review. Cancer Biomark. 2012;11(6):229–38.
2. Bhalla S, Kaur H, Kaur R, Sharma S, Raghava GPS. Expression based biomarkers and models to classify early and late-stage samples of Papillary Thyroid Carcinoma. PLoS One. 2020;15(4):e0231629. Published 2020 Apr 23. doi:10.1371/journal.pone.0231629
3. Geraldo MV, Kimura ET. Integrated analysis of thyroid cancer public datasets reveals role of post-transcriptional regulation on tumor progression by targeting of immune system mediators. PLoS ONE. 2015;10(11):e0141726.
4. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338-1348. doi:10.1001/jama.2017.2719
5. American Cancer Society, Cancer Facts & Figures. 2017; Atlanta, American Cancer Society.
6. Fraser S, Go C, Aniss A, et al. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World J Surg. 2016;40(7):1618-1624. doi:10.1007/s00268-016-3534-x
7. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020
8. Fazeli SR, Zehr B, Amraei R, et al. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule [published online ahead of print, 2020 Jun 19]. Thyroid. 2020;10.1089/thy.2019.0191. doi:10.1089/thy.2019.0191
9. Azizi G, Faust K, Mayo ML, Farrell J, Malchoff C. Diagnosis of Thyroid Nodule with New Ultrasound Imaging Modalities. VideoEndocrinology. 2020;7(1):ve.2020.0173. Published 2020 Mar 30. doi:10.1089/ve.2020.0173
10. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625.). (Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557–63.
11. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, et al. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res. 2004;10(6):2035–43.). (Sheils O. Molecular classification and biomarker discovery in papillary thyroid carcinoma [J]. Expert Rev Mol Diagn. 2005;5(6):927–46.
12. Qu M, Wan S, Ren B, Wu H, Liu L, Shen H. Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis [published online ahead of print, 2020 Apr 11]. Endocrine. 2020;10.1007/s12020-020-02284-7. doi:10.1007/s12020-020-02284-7.
13. Handkiewicz-Junak D, Swierniak M, Rusinek D, Oczko-Wojciechowska M et al. Gene signature of the post-Chernobyl papillary thyroid cancer. Eur J Nucl Med Mol Imaging 2016 Jul;43(7):1267-77. PMID: 26810418.
14. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57. doi:10.1038/nprot.2008.211.
15. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13. doi:10.1093/nar/gkn923.
16. Wang O, Zheng Z, Wang Q, et al. ZCCHC12, a novel oncogene in papillary thyroid cancer. J Cancer Res Clin Oncol. 2017;143(9):1679-1686. doi:10.1007/s00432-017-2414-6.
17. Jin Y, Jin W, Zheng Z, et al. GABRB2 plays an important role in the lymph node metastasis of papillary thyroid cancer. Biochem Biophys Res Commun. 2017;492(3):323-330. doi:10.1016/j.bbrc.2017.08.114.
18. Luo D, Chen H, Lu P, et al. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark. 2017;18(3):273-284. doi:10.3233/CBM-160255.
19. Zhang K, Liu J, Li C, Peng X, Li H, Li Z. Identification and validation of potential target genes in papillary thyroid cancer. Eur J Pharmacol. 2019;843:217-225. doi:10.1016/j.ejphar.2018.11.026.